177Lu-PSMA-617 Radioligand Treatment in Elderly Patients with Metastatic Castration-resistant Prostate Cancer: Therapeutic Efficacy and Safety Assessment

白细胞减少症 医学 前列腺癌 不利影响 不良事件通用术语标准 内科学 毒性 肌酐 胃肠病学 胆红素 肿瘤科 泌尿科 癌症
作者
Ertan Şahin,Umut Elboğa,Ufuk Çimen,Merve Okuyan,Yusuf Burak Çayırlı
出处
期刊:Current Radiopharmaceuticals [Bentham Science Publishers]
卷期号:17 (4): 356-363 被引量:4
标识
DOI:10.2174/0118744710284661240328094119
摘要

Objective: This study aimed to evaluate the therapeutic efficacy and safety of 177Lutetium-Prostate Specific Membrane Antigen (177Lu-PSMA-617) radioligand treatment (RLT) in metastatic castration-resistant prostate cancer (mCRPC) patients with aged older than 75 years. Methods: A total of 37 patients with mCRPC aged older than 75 years treated with 177Lu- PSMA-617 were included in this study. : Pre-therapy and post-therapy biochemical, metabolic, and clinical response results and Hb, TLC, platelet, serum creatinine and bilirubin levels were checked to evaluate the therapeutic efficacy and toxicity profile. The Common Terminology Criteria for Adverse Events was used for grading adverse events caused by 177Lu-PSMA-617 treatment. Results: The mean age of the patients included in the study was 79.8±2.9 (76-92). The number of 177Lu-PSMA-617 treatment cycles ranged from two to four, and the mean administered radioactivity dose was 5.6±0.8 GBq per cycle. Partial biochemical response (PR) and partial metabolic response (PMR) were observed in 11 (29.7%) and 15 (40.6%) patients after treatment, respectively. Although improvement in ECOG scores was observed in 5 (13.5%) patients after treatment, it was not statistically significant. Grade 2 and 3 Hb toxicity was observed in 10 (27%) and 2 (5.4%) patients, respectively. Grade 2 leukocytopenia in six patients, Grade 1 thrombocytopenia in six patients, and Grade 2 serum creatinine toxicity in five patients were seen after the treatment. On the other hand, no patients developed liver toxicity and grade 3 or 4 leukocytopenia, thrombocytopenia or creatinine toxicity. Conclusion: 177Lu-PSMA-617 treatment was a safe and effective treatment option for properly selected elderly mCRPC patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甄昕完成签到,获得积分10
刚刚
微笑的水桃完成签到 ,获得积分10
1秒前
哈哈哈完成签到,获得积分10
1秒前
1秒前
sonia0720完成签到,获得积分10
1秒前
1秒前
1秒前
香蕉觅云的应助被cola采纳,获得10
2秒前
月下思文完成签到 ,获得积分10
2秒前
kmkz发布了新的文献求助10
3秒前
3秒前
科研通AI6.4的应助被xpxpxpx采纳,获得10
3秒前
3秒前
善良丑完成签到 ,获得积分10
3秒前
4秒前
KeiQ完成签到,获得积分10
4秒前
小白鼠完成签到,获得积分10
4秒前
5秒前
zhenghua发布了新的文献求助10
6秒前
6秒前
6秒前
个性的小笼包完成签到,获得积分10
6秒前
Feng发布了新的文献求助10
6秒前
CC完成签到,获得积分10
7秒前
勤奋一一的应助被白英采纳,获得10
7秒前
8秒前
www发布了新的文献求助10
8秒前
8秒前
Since_2026完成签到,获得积分10
8秒前
bbabb完成签到 ,获得积分10
8秒前
小张困困发布了新的文献求助10
9秒前
学者11111发布了新的文献求助30
10秒前
困困困发布了新的文献求助10
10秒前
好好完成签到,获得积分10
10秒前
大头陈发布了新的文献求助10
10秒前
CipherSage的应助被Feng采纳,获得10
10秒前
tong完成签到,获得积分20
11秒前
11秒前
nnn发布了新的文献求助30
12秒前
123456hhh完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168144
求助须知:如何正确求助?哪些是违规求助? 9561199
关于积分的说明 21759542
捐赠科研通 7759434
什么是DOI,文献DOI怎么找? 3429948
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474463